Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
22 juil. 2024 08h00 HE
|
Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
09 juil. 2024 20h00 HE
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
GRI Bio Announces Closing of $4.0 Million Public Offering
28 juin 2024 16h05 HE
|
GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
27 juin 2024 09h15 HE
|
GT Biopharma, Inc.
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
20 juin 2024 08h00 HE
|
Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
14 juin 2024 08h03 HE
|
Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer. Earlier this year, scientists from Columbia University in New...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
11 juin 2024 09h00 HE
|
GRI Bio, Inc.
Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology...
Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path to More Personalized Treatments - A Free Webinar from the Brain & Behavior Research Foundation
03 juin 2024 13h19 HE
|
Brain & Behavior Research Foundation
New York, June 03, 2024 (GLOBE NEWSWIRE) -- NEW YORK -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path...
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31 mai 2024 12h00 HE
|
Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
Local startup Oncobiotix
Dew Aesthetics Unveils Cutting-Edge MedSpa Treatments in Baltimore, Pioneering a Path to Timeless Beauty
15 mai 2024 10h00 HE
|
Dew Aesthetics
BALTIMORE, Md., May 15, 2024 (GLOBE NEWSWIRE) -- Dew Aesthetics, the premier destination for cutting-edge medical spa treatments, is proud to announce the launch of its innovative services,...